To study the in vivo anti-tumor activity of PKMYT1i-ATRi combination, three patient-derived xenograft (PDX) models with CCNE1 amplification were utilized, including two OVCA (WO-19, WO-77) and one EMCA (WU-115) model (Fig. S3A-B). This evidence concerns the gene CCNE1 and neoplasm.